We use cookies to customise content for your subscription and for analytics.If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

In reasons released February 7, 2017, the Federal Court dismissed AstraZeneca’s application for a prohibition order regarding Mylan’s naproxen-esomeprazole product until after the expiration of Patent No. 2,449,098: AstraZeneca Canada Inc v Mylan Pharmaceuticals ULC, 2017 FC 142. The Court found that Mylan’s allegation of invalidity on the basis of obviousness was justified.